Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer

European Journal of Cancer

Volumn 36, Issue 6, 2000, Pages 694-709

  Decensi, A ^a   Costa, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; FENRETINIDE; RALOXIFENE; SELENIUM; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; ENDOMETRIUM CANCER; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034033954     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00040-X     Document Type: Review

References (86)

1. Sporn M.B., Newton D.L. Chemoprevention of cancer with retinoids. Fed. Procs. 38:1979;2528-2534.
2. Lippman S.M., Lee J.J., Sabichi A.L. Cancer chemoprevention. progress and promise J. Natl. Cancer Inst. 90:1998;1514-1528.
3. Gail M.H., Brinton L.A., Byar D.P.et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 81:1989;1879-1886.
4. Peipins L.A., Sandler R.S. Epidemiology of colorectal adenomas. Epidemiol. Rev. 16:1994;273-297.
5. Kinzler K.W., Nilbert M.C., Su L.K.et al. Identification of FAP locus genes from chromosome 5q21. Science. 253:1991;661-665.
6. Lynch HT, Lynch P. Hereditary and gastrointestinal tract cancer. In Lipkin M, Good RA, eds. Gastrointestinal Tract Cancer. New York, Plenum Press, 1978.
7. Macklin M.T. Inheritance of cancer of the stomach and large intestine in man. J. Natl. Cancer Inst. 244:1960;551-557.
8. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330:1994;1029-1035.
9. Clark L.C., Combs G.F.J., Turnbull B.W.et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. J. Am. Med. Assoc. 276:1996;1957-1963.
10. De Palo G., Veronesi U., Camerini T.et al. Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Inst. 87:1995;146-147.
11. Baserga R. The insulin-like growth factor I receptor. a key to tumor growth? Cancer Res. 55:1995;249-252.
12. Hankinson S.E., Willett W.C., Colditz G.A.et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
13. Chan J.M., Stampfer M.J., Giovannucci E.et al. Plasma insulin-like growth factor-I and prostate cancer risk. a prospective study Science. 279:1998;563-566.
14. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk. a case-control analysis J. Natl. Cancer Inst. 91:1999;151-156.
15. Ma J., Pollak M.N., Giovannucci E.et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91:1999;620-625.
16. Giovannucci E., Pollak M., Platz E.A.et al. Plasma insulin-like growth factor-I and binding protein-3 and risk of colorectal cancer and adenoma in women. Procs. Am. Assoc. Cancer Res. 40:1999;211.
17. Burroughs K.D., Dunn S.E., Barrett J.C., Taylor J.A. Insulin-like growth factor-I. a key regulator of human cancer risk J. Natl. Cancer Inst. 91:1999;579-581.
18. Kato S., Endoh H., Masuhiro Y.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
19. Torrisi R., Pensa F., Orengo M.A.et al. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res. 53:1993;4769-4771.
20. Torrisi R., Parodi S., Fontana V.et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int. J. Cancer. 76:1998;787-790.
21. Pollak M., Costantino J., Polychronakos C.et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst. 82:1990;1693-1697.
22. Boyd N.F., Byng J.W., Jong R.A.et al. Quantitative classification of mammographic densities and breast cancer risk. results from the Canadian National Breast Screening Study J. Natl. Cancer Inst. 87:1995;670-675.
23. Byrne C., Schairer C., Wolfe J.et al. Mammographic features and breast cancer risk. effects with time, age, and menopause status J. Natl. Cancer Inst. 87:1995;1622-1629.
24. Kato I., Beinart C., Bleich A., Su S., Kim M., Toniolo P.G. A nested case-control study of mammographic patterns, breast volume, and breast cancer. Cancer Cause Control. 6:1995;431-438.
25. Ursin G., Pike M.C., Spicer D.V., Porrath S.A., Reitherman R.W. Can mammographic densities predict effects of tamoxifen on the breast? J. Natl. Cancer Inst. 88:1996;128-129.
26. Boyd N.F., Greenberg C., Lockwood G.et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast. results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group J. Natl. Cancer Inst. 89:1997;488-496.
27. Boyd N.F., Fishell E., Jong R.et al. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention. Br. J. Cancer. 72:1995;476-479.
28. Powles T., Eeles R., Ashley S.et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
29. Veronesi U., Maisonneuve P., Costa A.et al. Prevention of breast cancer with tamoxifen. preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study Lancet. 352:1998;93-97.
30. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90:1998;1371-1388.
31. Veronesi U., Maisonneuve P., Costa A., Rotmensz N., Boyle P. Drop-outs in tamoxifen prevention trials. Lancet. 353:1999;244.
32. Decensi A., Robertson C., Rotmensz N.et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br. J. Cancer. 78:1998;572-578.
33. Jordan V.C., Fritz N.F., Langan-Fahey S., Thompson M., Tormey D.C. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J. Natl. Cancer Inst. 83:1991;1488-1491.
34. Gorin M.B., Day R., Costantino J.P.et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am. J. Ophthalmol. 125:1998;493-501.
35. Decensi A., Gandini S., Guerrieri-Gonzaga A.et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. J. Clin. Oncol. 17:1999;2633-2638.
36. Delmas P.D., Bjarnason N.H., Mitlak B.H.et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1997;1641-1647.
37. Jordan V.C., Glusman J.E., Eckert S.et al. Raloxifene reduces incident primary breast cancers. integrated data from multicentre, double-blind, placebo-controlled, randomized trials in postmenopausal women Breast Cancer Res. Treat. 50:1998;227.
38. Costa A., Formelli F., Chiesa F., Decensi A., De Palo G., Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 54:1994;2032s-2037s.
39. Fanjul A., Dawson M.I., Hobbs P.D.et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 372:1994;107-111.
40. Favoni R.E., de Cupis A., Bruno S.et al. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br. J. Cancer. 77:1998;2138-2147.
41. Lotan R. Retinoids and apoptosis. implications for cancer chemoprevention and therapy J. Natl. Cancer Inst. 87:1995;1655-1657.
42. Metha R.G., Moon R.C., Hawthorne M., Formelli F., Costa A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer. 27A:1991;138-141.
43. Veronesi U., De Palo G., Marubini E.et al. Randomized trial of fenretinide, a vitamin A analog, to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91:1999;1847-1856.
44. Sporn M.B. Combination chemoprevention of cancer. Nature. 287:1980;107-108.
45. Ratko T.A., Detrisac C.J., Dinger N.M., Thomas C.F., Kelloff G.J., Moon R.C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 49:1989;4472-4476.
46. Cobleigh M.A., Dowlatshahi K., Deutsch T.A.et al. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J. Clin. Oncol. 11:1993;474-477.
47. Conley B., O'Shaughnessy J., Prindiville S.et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J. Clin. Oncol. 18:2000;275-283.
48. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. (New York). 39:1997;1-20.
49. Rao C.V., Rivenson A., Simi B.et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472.
50. Waddell W.R., Ganser G.F., Cerise E.J., Loughry R.W. Sulindac for polyposis of the colon. Am. J. Surg. 157:1989;175-179.
51. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 90:1998;1529-1536.
52. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst. 90:1998;1609-1620.
53. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
54. Reddy B.S., Rao C.V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56:1996;4566-4569.
55. Oshima M., Dinchuk J.E., Kargman S.L.et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
56. Yang V.W., Shields J.M., Hamilton S.R.et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. 58:1998;1750-1753.
57. Donnelly M.T., Hawkey C.J. Review article. COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharm. Ther. 11:1997;227-2 36.
58. Sandler R.S. Epidemiology and risk factors for colorectal cancer. Gastroenterol. Clin. N. Am. 25:1996;717-735.
59. Baron J.A., Beach M., Mandel J.S.et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N. Engl. J. Med. 340:1999;101-107.
60. Verma A.K. The enzyme-activated irreversible inhibitor of ornithine decarboxylase, DL-alpha-difluoromethylornithine. a chemopreventive agent Prevent. Med. 18:1989;646-652.
61. Pegg A.E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 48:1988;759-774.
62. Meyskens F.L.J., Gerner E.W. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. J. Cell Biochem. 22(Suppl.):1995;126-131.
63. Love R.R., Jacoby R., Newton M.A.et al. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol. Biomarkers. 7:1998;989-992.
64. Greenberg E.R., Baron J.A., Tosteson T.D.et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N. Engl. J. Med. 331:1994;141-147.
65. MacLennan R., Macrae F., Bain C.et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J. Natl. Cancer Inst. 87:1995;1760-1766.
66. Omenn G.S., Goodman G.E., Thornquist M.D.et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334:1996;1150-1155.
67. Omenn G.S. Chemoprevention of lung cancer. the rise and demise of beta-carotene Ann. Rev. Pub. Health. 19:1998;73-99.
68. Hennekens C.H., Buring J.E., Manson J.E.et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149.
69. The Steering Committee of the Physicians' Health Study Research Group Physician's health study. aspirin and primary prevention of coronary heart disease N. Engl. J. Med. 321:1989;1825-1828.
70. McLarty J.W., Holiday D.B., Girard W.M., Yanagihara R.H., Kummet T.D., Greenberg S.D. Beta-carotene, vitamin A, and lung cancer chemoprevention. results of an intermediate endpoint study Am. J. Clin. Nutr. 62:1995;1431S-1438S.
71. Pastorino U., Infante M., Maioli M.et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol. 11:1993;1216-1222.
72. Hong W.K., Lippman S.M., Itri L.M.et al. Prevention of second primary tumors with isoretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323:1990;795-801.
73. Benner S.E., Pajak T.F., Lippman S.M., Earley C., Hong W.K. Prevention of second primary tumors with isoretinoin in patients with squamous cell carcinoma of the head and neck. longterm follow-up J. Natl. Cancer Inst. 86:1994;140-141.
74. Van Zandwijk N., Pastorino U., De Vries N., Dalesio O., Van Tinteren H. Randomized trial of chemoprevention with vitamin A and N-acetylsteine in patients with cancer of the upper and lower airways. the Euroscan Study Proc. ASCO. 18:1999;74.
75. Lee J.S., Lippman S.M., Benner S.E.et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J. Clin. Oncol. 12:1994;937-945.
76. Moon T.E., Levine N., Cartmel B.et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects. a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group Cancer Epidemiol. Biomarkers. 6:1997;949-956.
77. Levine N., Moon T.E., Cartmel B.et al. Trial of retinol and isotretinoin in skin cancer prevention. a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group Cancer Epidemiol. Biomarkers. 6:1997;957-961.
78. Tangrea J.A., Edwards B.K., Taylor P.R.et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma. a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group J. Natl. Cancer Inst. 84:1992;328-332.
79. Bavinck J.N., Tieben L.M., Van der Woude F.J.et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients. a double-blind, placebo-controlled study J. Clin. Oncol. 13:1995;1933-1938.
80. Blot W.J., Li J.Y., Taylor P.R.et al. Nutrition intervention trials in Linxian, China. supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population J. Natl. Cancer Inst. 85:1993;1483-1492.
81. Muto Y., Moriwaki H., Ninomiya M.et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334:1996;1561-1567.
82. Muto Y., Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med. 340:1999;1046-1047.
83. Meyskens F.L.J., Surwit E., Moon T.E.et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid. a randomized trial J. Natl. Cancer Inst. 86:1994;539-543.
84. Heinonen O.P., Albanes D., Virtamo J.et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene. incidence and mortality in a controlled trial J. Natl. Cancer Inst. 90:1998;440-446.
85. Taylor P.R., Albanes D. Selenium, vitamin E, and prostate cancer - ready for prime time? J. Natl. Cancer Inst. 90:1998;1184-1185.
86. Thompson I.M., Coltman C.A.J., Crowley J. Chemoprevention of prostate cancer. the Prostate Cancer Prevention Trial Prostate. 33:1997;217-221.